Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia

In this study, we investigated the prevalence of sexual dysfunction among males with advanced chronic kidney disease and effect treating hyperprolactinemia these patients. prospective patients were assessed history, physical examination, hormonal assessment, two questionnaires, IIEF AIPE. Patients received treatment cabergoline 0.5 mg once per week for 6 months re-evaluated. A total 102 included in 75 (73.53%) on hemodialysis, 13 (12.75%) peritoneal dialysis 14 (13.73%) medical alone. Ninety (88.24%) had premature ejaculation, 85 (83.33%) anything from mild-to-moderate-to-severe erectile dysfunction. The incidence hypogonadism was 34.4%. treated (n = 26) showed a significant increase LH levels (p .003) decrease prolactin .003). Testosterone or ejaculation did not improve significantly. There is high Treatment effective correcting levels, but does ejaculation. Therefore, an overall